Barlina Konwar, Kwang-sun Kim
The gut microbiota is recognized as a programmable metabolic organ that governs systemic homeostasis. Recent advances (2023-2025) have pivoted Type 2 Diabetes Mellitus (T2DM) research from a host-centric perspective toward a failure of bidirectional host-microbe metabolic flux. This review evaluates the molecular mechanisms underpinning this shift, focusing on microbial metabolite signaling, virome-mediated modulation, and the emergence of drug-microbiome interactions as critical therapeutic variables. We highlight the transformative role of AI-guided mapping and digital twin simulations in modeling high-resolution metabolic flux and predicting the stability of engineered microbial consortia. By integrating meta-transcriptomics and epigenomics, we characterize the functional plasticity of the microbiome under therapeutic stress. We argue that framing the microbiota as a programmable infrastructure-integrated with AI analytics and metabolic engineering-enables adaptive, real-time interventions. This synthesis offers a blueprint for transitioning from correlative observations toward precision microbiome engineering to achieve sustained metabolic resilience.